Why It Matters

Procter & Gamble faces a fundamental challenge: navigating a tariff regime that threatens to raise costs while jeopardizing the legal authority underpinning those tariffs. The consumer goods giant’s lobbying agenda this quarter centers on three interconnected threats.

First, reciprocal tariffs and Section 232 investigations could dramatically increase costs of imported raw materials and finished goods. Second, fragmented chemical and environmental regulation across states creates compliance complexity that federal clarification could alleviate. Third, international tax reform and OECD global minimum tax implementation require sophisticated coordination that could reshape P&G’s profit allocation across jurisdictions.

P&G’s legislative strategy reflects its desire to shape outcomes before tariff policy faces Supreme Court review, before pharmaceutical supply chain restrictions harden into law, and before state-level plastics regulations proliferate beyond management.

By the Numbers

Procter & Gamble Co. is a longstanding Washington player with over two decades of lobbying presence. The consumer goods giant has filed 78 in-house disclosures totaling approximately $70.97 million since August 2003.

In Q3 2025, P&G spent $751,000 through its eight-person in-house team on trade, taxation, chemical regulation, and pharmaceutical policy. The company added two new registered lobbyists this quarter: Matthew David Bisenius, a former Chief of Staff to Rep. Jim Sensenbrenner, and Bobbi Dillon, bringing specialized expertise on tariffs and tax policy.

The team includes Robert Joseph Cusmano, former Tax Counsel to Sen. Rob Portman, focusing on international tax reform and trade, and Sean Robert Mulvaney, a former House Policy Assistant who has filed 37 disclosures since 2016 worth nearly $29.5 million.

The Agenda

P&G’s most significant priorities include:

  • Trade and tariffs: Reciprocal tariffs, Section 232 investigations into softwood lumber and pharmaceutical tariffs, and "America First" trade policy
  • International taxation: The OECD Digital Tax Project and global minimum tax implementation, plus corporate and international tax provisions in H.R. 1
  • Chemical regulation: Reform of the Toxic Substances Control Act (TSCA)
  • Pharmacy and health: FDA review of over-the-counter product ingredients and H.R. 4273, the Over-the-Counter Monograph Drug User Fee Amendments
  • Environmental policy: Plastics recycling initiatives
  • Consumer safety: General product safety matters and ingredient disclosure requirements

Broader Context

Congress is actively reshaping trade and tax policy affecting P&G’s global operations. The administration has implemented the most aggressive tariff regime since the Great Depression, with average import duties surging to nearly 18%—but about half face Supreme Court challenges over presidential authority.

Pharmaceutical supply chain security has emerged as a bipartisan priority, with Congress advancing the Medical Supply Chain Resiliency Act and initiating a Section 232 investigation into pharmaceutical tariffs. Chemical regulation is in flux, with the EPA proposing rollbacks while lawmakers defend consumer product safety standards. Five states now require recycled content in plastic packaging, creating pressure for federal standards.

Between The Lines

The Senate Finance Committee and House Ways and Means Committee have held multiple hearings on reciprocal tariffs, though approximately half of current tariffs face Supreme Court challenges as potentially exceeding presidential authority.

On pharmaceutical supply chains, a House Energy and Commerce Health Subcommittee hearing focused on "Made in America" domestic manufacturing, creating favorable terrain for P&G’s advocacy. The Cosmetic Supply Chain Transparency Act of 2025 would mandate new ingredient disclosure requirements affecting P&G’s products.

Competitive Landscape

P&G isn’t alone in pursuing these priorities. The National Association of Manufacturers shares P&G’s focus on chemical regulation, while Walmart Inc. lobbies on overlapping tariff and trade policy issues. Cardinal Health Inc. overlaps with P&G’s pharmaceutical and environmental interests.

P&G’s specific focus on reciprocal tariffs, Section 232 pharmaceutical tariffs, and OECD digital tax implementation demonstrates a more proactive stance compared to broader industry coalitions.

The Bottom Line

P&G’s third quarter lobbying investment of $751,000 reflects standard corporate engagement on issues directly affecting supply chains, tax liability, and regulatory compliance. The effort occurs amid significant policy uncertainty, including pending Supreme Court challenges to tariff authority and shifting congressional attention to manufacturing resilience and supply chain security.

Spot something wrong? Report an issue with this article